.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,143,771

« Back to Dashboard

Summary for Patent: 6,143,771

Title: Compounds
Abstract:The novel optically pure compounds Na.sup.+, Mg.sup.2+, Li.sup.+, K.sup.+, Ca.sup.2+ and N.sup.+ (R).sub.4 salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H- benzimidazole or (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H- benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.
Inventor(s): Lindberg; Per Lennart (Molndal, SE), von Unge; Sverker (Fjar.ang.s, SE)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:09/419,456
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 8th percentile
Forward Citations: 5th percentile
Patent PDF download available with subscription

No matches for this query

Foreign Priority and PCT Information for Patent: 6,143,771

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9301830May 28, 1993

International Patent Family for Patent: 6,143,771

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria197452<disabled in preview>
Australia676337<disabled in preview>
Australia6902494<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc